• Explore /
  • Poster
  • / Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.

Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.

Abstract Poster

Authors

Diogo Bastos

Diogo Assed Bastos

Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

Diogo Assed Bastos , Rafael Coelho , Leonardo Cardili , Felipe Galiza , Eder Nisi Ilario , Públio Viana , Claudio Bovolenta Murta , Giuliano Guglielmetti , Mauricio Cordeiro , Jose Pontes Jr , David Queiroz Borges Muniz , Jamile Almeida Silva , Jose Mauricio Mota , Guilherme Fialho de Freitas , Katia Ramos Moreira Leite , Carlos Alberto Buchpiguel , William Carlos Nahas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT02789878

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5085)

DOI

10.1200/JCO.2022.40.16_suppl.5085

Abstract #

5085

Poster Bd #

268

Abstract Disclosures

Similar Posters

First Author: Ronald C. Chen

First Author: Rana R. McKay

First Author: John Nikitas

First Author: Alberto Carretero-González